eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 12
Poleć ten artykuł:
streszczenie artykułu:
Artykuł oryginalny

The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis

Magdalena Kaniewska, Andrzej Moniuszko, Grażyna Rydzewska

Data publikacji online: 2017/09/30
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Introduction: The biosimilar product Inflectra® has been approved by the European Medicine Agency (EMA) for the same indications as its reference drug, infliximab, based on studies in patients with rheumatic diseases. Thus far, there have not been enough data regarding its efficacy and safety in ulcerative colitis (UC).

Aim: To assess the efficacy and safety of the biosimilar product Inflectra® in comparison with its reference biological agent (Remicade®) in rescue therapy in adult patients presenting with severe exacerbation of UC, as well as to evaluate recurrence rate during a 6-month observation after finish of treatment.

Material and methods: In a single-centre retrospective study, a cohort of 83 adult patients with severe UC treated at the Department of Gastroenterology with Inflammatory Bowel Diseases Subdivision of the Central Clinical Hospital of MSWiA, Warsaw was investigated. All patients received three induction doses of Remicade® (28 individuals) or Inflectra® (55 individuals) based on the same criteria of the National Health Fund (NFZ) Therapeutic Program (total Mayo score > 6). Activity of the disease was evaluated on the Mayo scale at qualification, after finishing the rescue treatment (after 14 weeks), and after a 6-month observation period. In all patients, sigmoidoscopy was performed at qualification and after induction (after three doses).

Results: The studied groups were similar with respect to age and sex distribution, duration of the disease, extent of the disease (left-sided type, pancolitis), additional pharmacotherapy, and smoking. Clinical response following three induction doses was noted in 81% of patients receiving Remicade® compared to 77% receiving the biosimilar product, Inflectra® (NS); while clinical remission was observed in 42% receiving Remicade® and 32% receiving Inflectra® (NS), respectively. Endoscopic remission assessed as 0 on the Mayo scale was achieved in 4 (15%) patients on Remicade® and in 7 (13%) patients on Inflectra® (p = 0.45). Relapse occurred in 68% of all patients, while 51% presented with exacerbation of the disease 3 months after finishing biological treatment. In 93%, exacerbation occurred within 12 months. The recurrence rate was similar in both groups (75% with Remicade®, 64% with Inflectra®, respectively). Side effects occurred with similar frequency in both groups.

Conclusions: In the study, it was established that the biosimilar drug (Inflectra®) has a similar efficacy and safety as the reference biological agent (Remicade®), not only in rescue therapy, but also during a 6-month observation period in adult patients with severe UC. Low mucosal healing rate in both groups and high recurrence rate of the disease soon after finishing induction treatment indicate the need for prolonged therapy with infliximab in patients with severe UC.
Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 3: 1606-19.
Eder P, Łodyga M, Łykowska-Szuber L, et al. Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Prz Gastroenterol 2013; 8: 1-20.
Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-8.
Bartnik W. Wytyczne postępowania w nieswoistych chorobach zapalnych jelit. Prz Gastroenterol 2007; 2: 215-29.
Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965-90.
Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5-36.
Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis 2016; 10: 127-32.
Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006; 21 Suppl. 5: v4-8.
Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc 2004; 1: 24-9.
Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-6.
Sullivan E, Piercy J, Waller J, et al. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One 2017; 12: e0175826.
Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther 2017; 45: 1043-57.
Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9 (Suppl 1): 45-52.
Farkas K, Rutka M, Golovics PA, et al. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 2016; 10: 1273-8.
Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis 2017; 35: 91-100.
Harkin G, Keogh A, Slattery E. The effect of biosimilars [Inflectra®] in the management of acute severe ulcerative colitis. J Crohns Colitis 2017 jjx059. doi: 10.1093/ecco-jcc/jjx059.
Rydzewska G, Lipinski M. Biosimilars in gastroenterology – an important moment in the treatment of inflammatory bowel diseases. Int J Gastroenterol Disord Ther 2016; 3: 124.
Parasomthy S, Cleveland NK, Zmeter N, et al. The role of biosimilars in inflammatory bowel disease. Gastroenterol Hepat 2016; 12: 741-51.
Jahnsen J, Jorgensen KK. Experience with biosimilar Infliximab (Remsima®) in Norway. Dig Dis 2017; 35: 83-90.
Meder A, Świątkowski M, Meder G, et al. Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation. Prz Gastroenterol 2011; 6: 36-44.
Petryszyn P, Witczak I. Costs in inflammatory bowel diseases. Prz Gastroenterol 2016; 11: 6-13.
Dobrowolska-Zachwieja A, Jakubowska-Burek L. Korzyści leczenia biologicznego u osób z nieswoistymi chorobami zapalnymi jelit. Prz Gastroenterol 2010; 5: 68-76.
Stawowczyk E, Kawalec P. Cost-effectiveness of biological treatment of ulcerative colitis – a systematic review. Prz Gastroenterol 2017; 12: 90-7.
Morys JM, Kaczówka A, Jeżewska M. Assessment of selected psychological factors in patients with inflammatory bowel disease. Prz Gastroenterol 2016; 11: 47-53.
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe